GLP-3 Lets break down the key differences in a clear, comparative format: Primary Location of Action GLP-1: Pancreas, brain, stomach, cardiovascular system GLP-2: Intestinal tract, gut epithelium GLP-3: Unknown/under investigation Main Functions GLP-1: Regulates blood sugar Suppresses appetite Promotes weight loss Slows gastric emptying Protects cardiovascular system GLP-2: Promotes intestinal growth Enhances nutrient absorption Repairs gut lining Reduces inflammation Strengthens gut barrier GLP-3: Functions not well established Potentially metabolic or intestinal Requires more research Clinical Applications GLP-1: Type 2 diabetes treatment Obesity and weight management Cardiovascular disease prevention Potential neuroprotection GLP-2: Short bowel syndrome Inflammatory bowel disease (experimental) Intestinal injury recovery Malabsorption disorders GLP-3: No established clinical applications Currently research-only Half-Life GLP-1: Very short (2 minutes for natural form

In T2DM patients, lixisenatide reduced activation in brain areas including the hypothalamus, temporal lobar regions, lateral ventricle, and cortical areas in obese individuals in contrast to lean T2DM individuals, who showed increased activation in the areas [38]
At Element Sarms, the option to buy BPC-157 and TB-500 blend is restricted to research purposes
The habit stack makes the injection automatic rather than requiring active decision-making each week
The good news: you can manage it